{"id":"5-flourouracil","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Mucositis"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Leukopenia"},{"rate":"5-15%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL521800","moleculeType":"Small molecule","molecularWeight":"633.91"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA replication. This leads to the disruption of DNA synthesis and ultimately cell death in rapidly dividing cancer cells.","oneSentence":"5-fluorouracil is a thymidylate synthase inhibitor that disrupts DNA synthesis in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:19:52.468Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of colon cancer"},{"name":"Treatment of breast cancer"},{"name":"Treatment of stomach cancer"}]},"trialDetails":[{"nctId":"NCT03784326","phase":"PHASE2","title":"Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-02-19","conditions":"Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","enrollment":43},{"nctId":"NCT07201766","phase":"NA","title":"The Efficacy of Intralesional Bleomycin as Compared to 5-Flourouracil (5-FU) and Triamcinolone Acetonide (TAC) for the Treatment of Keloids: A Randomized Control Trial.","status":"NOT_YET_RECRUITING","sponsor":"King Edward Medical University","startDate":"2025-12-02","conditions":"Keloids Scars","enrollment":104},{"nctId":"NCT04329221","phase":"PHASE2","title":"Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2026-01-01","conditions":"Cutaneous Squamous Cell Carcinoma, Actinic Keratoses, Skin Cancer","enrollment":""},{"nctId":"NCT05467839","phase":"NA","title":"Evaluation of Efficacy of Microneedling and Topical Methotrexate Versus Microneedling and Topical 5-flourouracil in Treatment of Vitillgo Patients","status":"COMPLETED","sponsor":"Sohag University","startDate":"2022-07-31","conditions":"Vitiligo","enrollment":30},{"nctId":"NCT04747470","phase":"PHASE1","title":"Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-03-25","conditions":"Advanced Solid Tumors","enrollment":13},{"nctId":"NCT03421353","phase":"PHASE1","title":"AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-02-07","conditions":"Advanced Solid Tumours","enrollment":76},{"nctId":"NCT05631041","phase":"PHASE3","title":"Effect of Silymarin in Metastatic Colorectal Cancer Patients","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-12-31","conditions":"Metastatic Colorectal Cancer","enrollment":64},{"nctId":"NCT01726452","phase":"PHASE3","title":"NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2013-01-24","conditions":"Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction, Oesophageal Tumours","enrollment":377},{"nctId":"NCT01407107","phase":"PHASE1","title":"Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2011-01","conditions":"Rectal Cancer","enrollment":13},{"nctId":"NCT03279328","phase":"PHASE4","title":"Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2017-10-10","conditions":"Actinic Keratoses","enrollment":30},{"nctId":"NCT02425605","phase":"PHASE2","title":"Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2014-12-03","conditions":"Hepatocellular Carcinoma","enrollment":47},{"nctId":"NCT02358863","phase":"NA","title":"Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2015-02","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":13},{"nctId":"NCT03428529","phase":"PHASE2, PHASE3","title":"Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer.","status":"COMPLETED","sponsor":"Instituto Nacional de Cancer, Brazil","startDate":"2011-01-12","conditions":"Rectal Neoplasm Malignant","enrollment":63},{"nctId":"NCT01729481","phase":"PHASE2","title":"Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2012-07","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":150},{"nctId":"NCT01941953","phase":"PHASE2","title":"Metformin and 5-fluorouracil for Refractory Colorectal Cancer.","status":"COMPLETED","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2012-11","conditions":"Metastatic Colorectal Cancer","enrollment":50},{"nctId":"NCT00022178","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin","status":"UNKNOWN","sponsor":"The Christie NHS Foundation Trust","startDate":"1998-12","conditions":"Carcinoma of Unknown Primary","enrollment":""},{"nctId":"NCT01945879","phase":"PHASE1, PHASE2","title":"Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer","status":"COMPLETED","sponsor":"CONKO-Studiengruppe","startDate":"2003-01","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT00023959","phase":"PHASE1","title":"Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-07","conditions":"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip","enrollment":39},{"nctId":"NCT00277017","phase":"PHASE1, PHASE2","title":"Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma","status":"COMPLETED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2000-09","conditions":"Kidney, Cancer","enrollment":15},{"nctId":"NCT00024141","phase":"PHASE1","title":"Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2001-05","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00255476","phase":"PHASE2","title":"The IRESSA Novel Head and Neck Chemotherapy Evaluation Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-02","conditions":"Squamous Cell Cancer, Cancer of Head and Neck","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":218,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["5-FU"],"phase":"phase_2","status":"active","brandName":"5-flourouracil","genericName":"5-flourouracil","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"5-fluorouracil is a thymidylate synthase inhibitor that disrupts DNA synthesis in rapidly dividing cancer cells. Used for Adjuvant treatment of colon cancer, Treatment of breast cancer, Treatment of stomach cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}